AGNG vs IHI

Key Takeaways

• AGNG offers thematic exposure to global aging population trends with 91% in healthcare and 9% in real estate (senior living), while IHI provides concentrated U.S. medical devices focus at 100% healthcare.
• IHI has a lower expense ratio of 0.38% compared to AGNG's 0.50%, appealing to cost-conscious investors seeking sector purity.
• AGNG holds 84 stocks for broader diversification versus IHI's 47 holdings, where top 10 comprise over 75% of assets, increasing concentration risk.
• Both ETFs share medical device overlap like EW, but AGNG includes pharmaceuticals and biotech for longevity plays.
• Recent market cycles show AGNG delivering steadier returns tied to demographic tailwinds, while IHI exhibits higher volatility from device innovation cycles.
• Liquidity favors IHI with billions in AUM and high daily volume, versus AGNG's smaller scale.

Introduction

AGNG and IHI represent complementary strategies within healthcare, a defensive sector amid economic uncertainty and technological disruption. AGNG targets the global aging population theme, capturing companies benefiting from extended lifespans through pharmaceuticals, biotech, and senior care. IHI, conversely, hones in on U.S. medical device manufacturers driving procedural innovations like robotics and diagnostics. While not direct competitors, both ETFs appeal to investors eyeing healthcare's resilience—fueled by demographics and medtech advances—offering alternatives for thematic breadth versus specialized equipment exposure in recent market rotations toward quality growth.

Global X Aging Population ETF (AGNG) Overview

The Global X Aging Population ETF (AGNG) is a passive, thematic fund launched in 2016 that tracks the Indxx Aging Population Thematic Index. It invests in global companies deriving significant revenue from products and services for seniors, including healthcare, pharmaceuticals, biotechnology, medical devices, and senior living facilities. With 84 holdings and top 10 accounting for about 32%, AGNG emphasizes modified market-cap weighting with caps for diversification. Key top holdings include Novo Nordisk A/S (3.8%), WELL (3.2%), VTR (3.2%), EW (3.1%), and Roche Holding AG (3.1%). Sector allocation stands at 91% healthcare and 9% real estate. The expense ratio is 0.50%, with semi-annual distributions and lower volatility (beta around 0.6 to S&P 500). The index rebalances annually, ensuring alignment with aging demographics.

iShares U.S. Medical Devices ETF (IHI) Overview

The iShares U.S. Medical Devices ETF (IHI), launched in 2006, passively tracks the Dow Jones U.S. Select Medical Equipment Index, focusing on U.S. companies manufacturing and distributing non-disposable medical devices like imaging systems, pacemakers, and prosthetics. It holds 47 stocks, with top 10 comprising over 75% of assets for concentrated exposure. Leading holdings feature ISRG (16.7%), ABT (15.7%), SYK (around 10%), EW (5%), and BSX. Allocation is 100% healthcare equipment. The expense ratio is a competitive 0.38%, with quarterly distributions and higher trading volume reflecting strong liquidity. The non-diversified structure amplifies sector-specific dynamics, with the index employing market-cap weighting.

Industry and Thematic Backdrop

Healthcare remains resilient amid macroeconomic shifts, driven by aging populations—projected to boost demand for longevity therapies and senior care—and medtech innovations like AI-enabled robotics and remote monitoring. Capital flows favor defensive growth, with catalysts including robust drug pipelines, procedural volume recovery post-pandemic, and policy support for home-based care. Regulatory scrutiny on pricing (e.g., Medicare reforms) and tariffs on devices pose risks, alongside workforce shortages and cybersecurity threats. Recent cycles highlight sector rotation toward quality names resilient to interest rate fluctuations, positioning both ETFs amid demographic tailwinds and technological catalysts.

Performance and Positioning Comparison

In recent months, AGNG has shown relative stability, benefiting from broad healthcare diversification and pharma strength, with 1-year returns around 14% tied to consistent demographic demand. IHI, more sensitive to innovation cycles and procedural growth, has faced higher volatility, posting negative returns over similar periods amid supply chain pressures and elevated valuations in top holdings like ISRG. AGNG's global scope and real estate buffer reduce beta versus IHI's U.S.-centric device focus, which amplifies swings from earnings in medtech leaders. Sector momentum favors aging themes over pure devices in uncertain environments, though IHI leads in high-growth procedural upcycles.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization (market cap), technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, empowering data-driven decisions across asset classes. Explore it today to uncover hidden gems in sectors like healthcare.

Tickeron AI Verdict

Tickeron’s AI currently favors AGNG for its structural advantages in diversification, global thematic alignment with unstoppable aging trends, and balanced risk profile amid volatile markets. While IHI offers cost efficiency and liquidity in a high-growth niche, AGNG's broader exposure and lower concentration mitigate downside risks, with probabilistic edge in consistent trend capture over recent cycles.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations